Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
Cells · 11.04.2023 · 12 (8) · 1135
DOI: 10.3390/cells12081135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 11.04.2023. Verfasst von Lorenza Pecciarini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of Lung. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The ability to identify the broadest range of targetable gene fusions is crucial to facilitate personalized therapy selection for advanced lung adenocarcinoma (LuADs) patients harboring targetable receptor tyrosine kinase (RTK) genomic alterations. In order to evaluate the most effective testing approach for LuAD targetable gene fusion detection, we analyzed 210 NSCLC selected clinical samples, comparing in situ (Fluorescence In Situ Hybridization, FISH, and ImmunoHistoChemistry, IHC) and molecular (targeted RNA Next-Generation Sequencing, NGS, and RealTime-PCR, RT-PCR) approaches. The overall concordance among these methods was high (>90%), and targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements at the RNA level. However, we observed that FISH was useful to detect targetable fusions in those samples with inadequate tissue material for molecular testing as well as in those few cases whose fusions were not identified by the RNA NGS panel. We conclude that the targeted RNA NGS analysis of LuADs allows accurate RTK fusion detection; nevertheless, standard methods such as FISH should not be dismissed, as they can crucially contribute to the completion of the molecular characterization of LuADs and, most importantly, the identification of patients as candidates for targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- Department of Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy.
ORCID-Profile: Miriam Redegalli, Maria Giulia Cangi
Zitieren
APA
Pecciarini, L., Brunetto, E., Grassini, G., De Pascali, V., Ogliari, F. R., Talarico, A., Marra, G., Magliacane, G., Redegalli, M., Arrigoni, G., Lazzari, C., Gregorc, V., Bulotta, A., Doglioni, C., & Cangi, M. G. (2023). Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?. Cells, 12(8), 1135. https://doi.org/10.3390/cells12081135
Vancouver
Pecciarini L, Brunetto E, Grassini G, De Pascali V, Ogliari FR, Talarico A, et al. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?. Cells. 2023;12(8):1135. doi:10.3390/cells12081135
BibTeX
@article{Pecciarini2023,
author = {Pecciarini, Lorenza and Brunetto, Emanuela and Grassini, Greta and De Pascali, Valeria and Ogliari, Francesca Rita and Talarico, Anna and Marra, Giovanna and Magliacane, Gilda and Redegalli, Miriam and Arrigoni, Gianluigi and Lazzari, Chiara and Gregorc, Vanesa and Bulotta, Alessandra and Doglioni, Claudio and Cangi, Maria Giulia},
title = {Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?},
journal = {Cells},
year = {2023},
volume = {12},
number = {8},
pages = {1135},
doi = {10.3390/cells12081135}
}
EUVIMED